About ERIX
EiRx Therapeutics is a specialist provider of pre-clinical therapeutics to the pharmaceutical industry. Our unique scientific expertise and knowledge in the field of Apoptosis provide a sound base to discover and develop new medicines that will safely and selectively repair this natural process in disease. The potential benefits from these new medicines are enormous, since as many as 70% of all human disease have some defect in the control of Apoptosis.
Apoptosis - the biological process that determines whether cells in our bodies live or die...
http://www.eirx.com/index.html

Purchased some of these on the strength of the PROGRESS UPDATE looks promising.
http://moneyam.uk-wire.com/cgi-bin/articles/200603200701130254A.html

ERX interview with John Pool
http://www.wallstreetreporter.com/interview.php?id=18589&player=real
Latest News
CANCER COLLABORATION WITH BIOMERIEUX SA
http://moneyam.uk-wire.com/cgi-bin/articles/200607120700230534G.html
Biomerieux Web Site
http://www.biomerieux.com/servlet/srt/bio/portail/home
ABOUT ERX Focus Of The Month
http://www.billamag.net/focus-document-text.asp?FocusTextID=1
ERX pdf filehttp://www.eirx.com/eirx_heading_images/Yokohama2005.pdf
19/09/2006 A 50% reduction in breast tumour volume size seen with Eirx lead molecule in animal studies
http://moneyam.uk-wire.com/cgi-bin/articles/200609190700171175J.html

Past and present collaborative partners include:

* bioMieux SA
* Almac Diagnostics Ltd
* Merck & Co, Ltd
* Biofocus plc
* MGI Pharmaceuticals, Inc
* OSI Pharmaceuticals, Inc
* Sareum plc
* Regen Therapeutics plc
* SR Pharma plc

French pharmaceutical company to invest up to E185 million in R&D



Release date: 27 Oct 2006



The investment by the French pharmaceutical company, Servier, of between 115 million and 185 million in research and production signals its long-term commitment to Ireland, writes Lara Marlowe in The Irish Times, October 27.

Servier established a plant in Arklow, Co Wicklow, in November 1989 which now supplies medicines for the company's Canadian, European, South African and Australian markets.

Today, the company will announce a 70 million investment that will double its capacity in order to keep pace with demand.

By 2010, Arklow will produce 140 million boxes of medicine each year.

Servier is also investing E45 million in a plant at the Belview industrial estate on the Kilkenny/ Waterford border that will produce active pharmaceutical ingredients for three new Servier products: Ivabradine (whose market name is Procoralan), which regulates heart rhythm; the anti-depressant Agomelatine (Valdoxan) and Terutroban, which protects the walls of the arteries.

Servier says it is 'almost certain, depending on the evolution of the market,' that his company will decide early next year to invest a further E55 million-E70 million at Belview - to manufacture Strontium Ranelate (Protelos), a drug invented by Servier laboratories to stop osteoporosis in post-menopausal women. The site would employ 155 people by 2014.

The manufacturing plants are not the French company's only involvement with Ireland.

Yesterday, October 26, French scientist Dr Marc Devocelle, a member of the Royal College of Surgeons in Ireland, received the E10,000 Dr Jacques Servier prize.

The two-year-old prize is one example of Servier's constant emphasis on research. The firm has invented 30 new medicines in as many years and recycles 25 per cent of its turnover back into research - double the average for the industry in France.

Servier already conducts research in Ireland through individual contracts with the Conway Institute at University College Dublin. The company has even established the Servier chair of molecular pharmacology, currently held by Eoin O'Brien.

Servier's intention to further strengthen research activity in Ireland coincides with the Taoiseach's recent announcement of a multibillion euro investment in research in coming years.

'Twenty years ago, no one thought of Ireland as a country for research,' Servier says. 'The Irish have made an extraordinary effort, even more impressive than Canada's.

'Research creates good jobs and it is unlimited. Medical research cannot satisfy needs for at least another century. It's the discovery of new products that keeps a laboratory alive.'

Last summer, executives from Servier met Minister of Health and Children, Mary Harney.

'She wanted to show how keen the Irish Government is to develop medical research in Ireland,' says Christian Bazantay, the secretary general of Servier, who looks after much of the daily running of the company for Servier.

'Ireland is a country that likes the pharmaceutical industry, that is proud to have a highly developed pharmaceutical sector. All the big laboratories are present in Ireland.'

A glance through statistics provided by IDA Ireland shows how significant a part of the economy pharmaceutical companies have become.

Thirteen of the world's top 15 pharmaceutical companies have substantial operations in Ireland. There are 83 foreign-owned pharmaceutical facilities in Ireland. The sector employs 17,000 people and had a production value of E34 billion in 2002.

Servier compares Ireland to Switzerland. 'The Swiss have had the same policy towards pharmaceuticals since the time of the French Revolution,' he says.

'It's been a complete success, a considerable, reliable source of wealth. Ireland and Switzerland are both countries with few natural resources but talented populations.'

Servier established the Arklow plant in 1989.

'Our clients didn't like the fact that everything was manufactured in France,' Servier adds. 'They were afraid of another world war or a revolution.

'Among the prejudices about France, there is always the image of a revolutionary country. They wanted a peaceful country, which is why we thought of going to Ireland, a neutral country and what was more, an island.'

The company was also seduced by IDA Ireland, which took Servier and Bazantay on a tour of 200 sites, including a salmon-stocked river near a ruined castle, so beautiful that Servier refused to build a plant there. The IDA arranged appointments with high-ranking officials and negotiated a grant agreement, which subsidised the creation of Irish jobs.

Servier says Ireland's 12.5 per cent corporate tax rate 'wasn't what made up our minds, even if it was pleasant' - especially when compared with the 33 per cent rate in France.

He admits his company considered the zero corporate tax offered by Estonia, but found the language and small population an obstacle.

'When we're happy in a country, that comes before everything else,' he says. 'I don't want to tempt fate, but I think we would stay in Ireland (even if the corporate tax rate changed and the IDA stopped grants).'

Another advantage of working in Ireland is the relative absence of what Servier calls 'red tape' or dirigisme.

After a new medicine is registered, the pharmaceutical company negotiates its price with the Government. In Ireland, the process takes three months; in France, Italy and Spain, it takes more than a year.

Only recently, Servier says, has the French government realised the importance of investing more in research and helping rather than hindering its pharmaceutical industry, the biggest in Europe.

Pharmaceuticals are a slow industry that is forced to work fast. 'We apply for a patent the day we discover a molecule,' Servier explains.

'It then takes 12 years to develop the product, which leaves only eight years of exclusive rights until the patent runs out and we are into price competition. One year out of eight is a huge amount of time to lose.'

He says his decision, half a century ago, to turn Servier into a foundation, is the way of the future.

'I was always alarmed at the difficulties encountered on the stock market by companies in slow professions like ours,' he explains. 'We have never had to pay dividends, so we can reinvest our profits in research.

'If you have pension funds as shareholders, you are under pressure to pay high dividends. This western financial system was fabulous, because it made it possible to build railroads, ports and cities. But it's outdated for industries with a long lead time.'

Source: The Irish Times, October 27

I wonder if its the whole 165mil euro that we are getting, or just a percentage

Pot Head chill out ! if erx were going to get 165 mil euro i would think by now the sp would be a bit better dont you !! just wait for the facts, who knows !! :)

Smiler o

I can't understand your thinking all that dropping the price does is increase people to buy more shares as your see from this mornig.

Marcel, I agree although it could just be a MM mind game ? but this share over the last 2 weeks has been up and down a fair bit so not to worried, :)

its been tipped twice iver the two weeks in the Express and the FT..

Brokers have it down as strong buy..

cash coming soon, and lots of it

Marcel,
I can only get 25,000 online at the moment ???

Tell me about it, so why the share not going up?

yes it is frustrating but it was like this last week, we might get a tic up soon with luck ! :)

10mil T trade due to rollover, I assume its today

here we go, about to go blue!!!!

City Equities

EiRx can spot the difference
Developing potential cancer treatments has become somewhat of a holy grail amongst biotech companies, but it is eirxs expertise in
apoptosis that the Board believes sets it apart from the pack. EiRx was formed in 1999 and debuted on AiM in 2004. Focusing on cancer therapies, with par-ticular attention on breast and colorectal cancer, the Company aims to leverage its knowledge of the Apoptosis process by which cells die in a reg- ulated manner and are absorbed into the body. This aim is also assisted by use of the Companys two core technologies. These are the ALiBi plat- form and the Engineered Pathway Dependence Screening Platform, or EnPAD, which have been developed to find and develop genes involved in the early stages of apoptosis that could become targets for novel therapeutic treatments. it could certainly be said that the potential mar- ket for a company engaged in this kind of work is considerable, especially when it is estimated* that up to 70% of all human diseases have some sort of defect in apoptosis control. EiRx currently has more than 15 patent applications pending in both the UK and US and a further development to the story came in September, when the Company announced that trials con- ducted on mice had shown a 50% reduction in breast tumour volumes, with good tolerance to the compound and no toxic or side effects. Pro- fessor Tom Cotter, CEO, commented at the time a reduction in tumour volume of 50% is seen by the National Cancer institute in America and
other leading authorities as being highly signifi- cant. it was estimated* that 443,000 women in 2004, across the seven major markets had developed breast cancer and forecasts indi- cated an annual increase to this at a rate of 3%. When you also consider colorectal cancer is the number two cause of cancer related deaths worldwide, EiRxs focus seems to be timely. it is therefore obvious that a therapy, which suc- cessfully differentiates between cancerous and non-cancerous cells has huge potential and we look forward to further updates as development continues in this worthwhile cause.
(*Source: EiRx Therapeutics) n eIrx THerAPeuTIcS
Status AIM
Code ERX.L
Recent Price 0.25p (0.22p-0.28p)
High 0.33p
Low 0.13p
Market Cap 6.8m

http://www.cityequities.com/campaigns/t!ps002/landing.asp

Driver
It was one of about ten pharma recommendations though.

laurie
Fair point but only a couple of months ago it was only the small punter that new about ERX, now D/Express, FT, City Equities who will be next all looking good for the coming weeks.

about to rocket

I'm predicting bonfire night.

HOPE YOU LOT ARE RIGHT WITH ALL THE HYPE I,AM HOLDING 5M @ .0018p-0025p ?

I have 34mil.. at ave of 25

GOOD LUCK POTHEAD

news out tomorrow 700202